priors.science/reviews/cardiac-amyloidosis

Cardiac Amyloidosis

The current evidence on 19 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

19claims tracked
142primary papers reviewed
9 Aug 2026latest evidence review
Weeklyre-scored against new papers
4 Established · 7 Likely · 6 Uncertain · 2 Doubtful  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
Daratumumab plus bortezomib, cyclophosphamide and dexamethasone improves light-chain amyloidosis responseAL TreatmentEstablished92%15
National Amyloidosis Centre staging stratifies transthyretin amyloid cardiomyopathy prognosisStaging PrognosisEstablished90%8
Technetium pyrophosphate scintigraphy diagnoses transthyretin amyloid cardiomyopathyDiagnosisEstablished88%6
Tafamidis reduces mortality in transthyretin amyloid cardiomyopathyTTR StabilisersEstablished86%10
Acoramidis reduces mortality in transthyretin amyloid cardiomyopathyTTR StabilisersLikely84%18
Vutrisiran reduces mortality in transthyretin amyloid cardiomyopathyTTR SilencingLikely82%8
Haematologic response depth predicts light-chain amyloidosis survivalAL TreatmentLikely72%6
Tafamidis efficacy in wild-type and variant transthyretin amyloidosisTTR StabilisersLikely71%8
CRISPR TTR editing reduces serum TTR by 90%Emerging TherapiesLikely70%5
NT-proBNP predicts transthyretin amyloid cardiomyopathy mortalityStaging PrognosisLong-standingLikely70%15
Early tafamidis initiation gives superior survivalTTR StabilisersLikely70%10
V142I transthyretin amyloid cardiomyopathy has worse prognosisStaging PrognosisUncertain64%6
Patisiran preserves function in transthyretin cardiac amyloidosisTTR SilencingUncertain58%15
TTR silencing reduces serum TTR over 80%TTR SilencingLong-standingUncertain55%15
Transthyretin amyloidosis therapy and transcatheter aortic valve replacement improve aortic stenosis outcomeHF ManagementUncertain53%6
Transthyretin amyloid cardiomyopathy underdiagnosed in heart failure with preserved ejection fractionDiagnosisUncertain52%6
Tafamidis preserves left ventricular mass and functionTTR StabilisersUncertain52%8
Mineralocorticoid receptor antagonist use reduces mortality in transthyretin amyloid cardiomyopathyHF ManagementDoubtful48%4
Eplontersen reduces TTR in transthyretin amyloid cardiomyopathyEmerging TherapiesDoubtful47%5
Track Cardiac Amyloidosis.
These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it — confidently false as stated.
Where the evidence sits in time
Long-standingMost of this evidence is older than the rest of this field.